BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1707957)

  • 1. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
    Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
    J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA).
    Klepp O; Flodgren P; Maartman-Moe H; Lindholm CE; Unsgaard B; Teigum H; Fosså SD; Paus E
    Ann Oncol; 1990 Jul; 1(4):281-8. PubMed ID: 1702312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The search for biomarkers of metastatic seminoma.
    Ruf CG; Khalili-Harbi N; Sachs S; Isbarn H; Wagner W; Matthies C; Meineke V; Fisch M; Chun FK; Abend M
    J Urol; 2013 Sep; 190(3):1046-51. PubMed ID: 23583226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group.
    Rørth M; Jacobsen GK; von der Maase H; Madsen EL; Nielsen OS; Pedersen M; Schultz H
    J Clin Oncol; 1991 Sep; 9(9):1543-8. PubMed ID: 1714948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in metastatic testicular cancer.
    Vogelzang NJ
    Int J Androl; 1987 Feb; 10(1):225-37. PubMed ID: 2438220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
    Klepp O; Olsson AM; Henrikson H; Aass N; Dahl O; Stenwig AE; Persson BE; Cavallin-Ståhl E; Fosså SD; Wahlqvist L
    J Clin Oncol; 1990 Mar; 8(3):509-18. PubMed ID: 1689773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
    Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
    J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
    Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
    Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
    Fosså SD; Qvist H; Stenwig AE; Lien HH; Ous S; Giercksky KE
    J Clin Oncol; 1992 Apr; 10(4):569-73. PubMed ID: 1312586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ; Norman AR; Dearnaley DP; Horwich A
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
    Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
    J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical studies of testicular tumor. II. Analysis of 30 patients with nonseminomatous testicular tumor].
    Tsukamoto T; Kumamoto Y; Ohmura K; Tsunekawa T; Yamazaki K
    Hinyokika Kiyo; 1986 Jul; 32(7):999-1011. PubMed ID: 2430437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Significance of a Small Component of Choriocarcinoma in Testicular Mixed Germ Cell Tumor (MGCT).
    Hassan O; Epstein JI
    Am J Surg Pathol; 2018 Aug; 42(8):1113-1120. PubMed ID: 29794869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonseminomatous germ cell tumors of the testis: current concepts and controversies.
    Sheinfeld J
    Urology; 1994 Jul; 44(1):2-14. PubMed ID: 7518979
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
    Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
    Davis BE; Herr HW; Fair WR; Bosl GJ
    J Urol; 1994 Jul; 152(1):111-3; discussion 114. PubMed ID: 7515445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.
    Steyerberg EW; Keizer HJ; Zwartendijk J; Van Rijk GL; Van Groeningen CJ; Habbema JD; Stoter G
    Br J Cancer; 1993 Jul; 68(1):195-200. PubMed ID: 8318413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.